Alumis (ALMS) stock price is $6.70, up 5.68% on the day, as of Oct 20, 2026. It has a market cap of $854.95Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap854.95 Mn
P/E-2.98
P/S102.72
Div. Yield0.00
Revenue Growth (1y) (Qtr)-37.66
Add ratio to table…
About
Alumis Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients with immune mediated diseases by replacing broad immunosuppression with targeted therapies. The company name reflects its mission to illuminate immunology derived from the French word allumer meaning to light up and the Latin word immunis relating to the immune system. Alumis uses a proprietary precision data analytics platform that integrates genomic and proteomic…
Alumis Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients with immune mediated diseases by replacing broad immunosuppression with targeted therapies. The company name reflects its mission to illuminate immunology derived from the French word allumer meaning to light up and the Latin word immunis relating to the immune system. Alumis uses a proprietary precision data analytics platform that integrates genomic and proteomic information to identify disease mechanisms and to select optimal drug targets molecules indications patients and clinical endpoints. Its lead product candidates are two tyrosine kinase 2 inhibitors: envudeucitinib (envu) a second generation allosteric TYK2 inhibitor being advanced for moderate to severe plaque psoriasis and systemic lupus erythematosus and A-005 a central nervous system penetrant allosteric TYK2 inhibitor intended for neuroinflammatory and neurodegenerative conditions. Through the ACELYRIN merger Alumis also acquired lonigutamab a subcutaneous monoclonal antibody that binds IGF-1R for the potential treatment of thyroid eye disease. Beyond these programs the company continues to explore earlier stage targets such as interferon regulatory factor 5 and other molecules discovered via its precision approach to broaden its pipeline of immune modulating therapies.
As a clinical stage enterprise Alumis Inc. has not yet recorded any revenue from the sale of approved products. The company finances its research development and general and administrative activities primarily through proceeds from public equity offerings and private placements. It may also pursue funding through strategic collaborations grants or other financing arrangements when appropriate. Alumis does not maintain an internal manufacturing facility nor a commercial sales organization reflecting its pre revenue status. The company intends to develop a commercial infrastructure including sales marketing distribution and market access capabilities only after its product candidates receive regulatory approval.
Alumis Inc. operates in a highly competitive segment of the biopharmaceutical industry where large multinational pharmaceutical companies specialty biotechs and generic drug manufacturers vie for share in treatments for immune mediated diseases. The company differentiates itself through a precision medicine strategy that leverages human genetic data biological insights and proprietary analytics to prioritize targets with strong validation and to design molecules with favorable drug like properties. Its lead asset envu is positioned as a selective allosteric inhibitor of tyrosine kinase 2 that demonstrates high potency and intrinsic selectivity over other janus kinase family members. Preclinical and clinical data show that envu achieves rapid systemic absorption favorable tissue distribution a predictable linear pharmacokinetic profile and a half life of approximately eight to twelve hours in humans. Importantly envu has not exhibited the joint related or cardiovascular safety signals that have been observed with some first generation TYK2 inhibitors. These characteristics aim to provide an improved benefit risk profile compared with broad immunosuppressive therapies and may support its competitiveness in indications such as psoriasis systemic lupus erythematosus and potential neuroimmune conditions. The company also notes that the TYK2 pathway is implicated in a wide range of diseases including psoriasis psoriatic arthritis inflammatory bowel disease multiple sclerosis and systemic lupus erythematosus offering a broad addressable market for its therapeutic approach.
Alumis Inc. does not yet serve commercial customers because its product candidates remain under clinical investigation. Upon potential approval the company intends to treat patients suffering from immune mediated diseases such as moderate to severe plaque psoriasis systemic lupus erythematosus thyroid eye disease and possibly neuroinflammatory disorders including multiple sclerosis. The commercial strategy envisions engagement with dermatologists rheumatologists gastroenterologists neurologists and other specialists who manage these conditions. Alumis also expects to interact with healthcare payers including government programs private insurers and pharmacy benefit managers to secure coverage and reimbursement for its therapies. The company plans to pursue market access in the United States the European Union and the Asia Pacific region either directly or through partnerships with established pharmaceutical firms. No specific customer names are disclosed in the filing.
Sector:HealthcareSector rationaleAlumis is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases, specifically tyrosine kinase 2 inhibitors like envudeucitinib. Its core business activity is the discovery and clinical development of pharmaceuticals, which falls squarely within the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryAlumis is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like lonigutamab and targeted inhibitors for immune-mediated diseases. Its business model focuses on biology-based drug discovery and development using a precision data analytics platform integrating genomic and proteomic information.Classified using BQ-MICSCIK: 0001847367
Bull & bear
Investment Thesis
▲ Bull case
The trial results showed that about sixty five% of patients achieved a ninety% or greater improvement in skin symptoms after twenty four weeks of treatment. This level of efficacy exceeds what was seen with many existing therapies and suggests the drug could deliver a best in class profile. More than forty% of patients experienced complete skin clearance which is a meaningful endpoint for regulators and payers. Such high rates of PASI 90 and PASI 100 responses indicate a strong therapeutic signal that may support premium pricing. The data were described as stronger than expected by analysts which implies the market may have underestimated the drug's potential. Overall the efficacy data create a solid foundation for future commercial success.
The addressable market for moderate to severe plaque psoriasis in the United States exceeds eight million patients according to the National Psoriasis Foundation. Globally the number of affected individuals is substantially larger providing a multi billion dollar opportunity. Capturing even a modest share of this patient base could translate into significant annual revenues for the company. The drug’s mechanism targeting TYK2 offers a differentiated approach compared with older cytokine blockers. Expansion into additional immune mediated diseases such as lupus further broadens the potential market. These factors together suggest a long runway for growth beyond the initial psoriasis indication.
Alumis has stated it plans to seek U S regulatory approval for envudeucitinib in the second half of the current year. A successful approval would allow the company to begin commercial sales and generate cash flow sooner than many investors anticipate. Management has also indicated that there should be interest from potential strategic partners for the asset. A partnership or licensing deal could provide upfront payments milestones and royalties reducing the need for dilutive financing. The combination of a near term regulatory catalyst and partnership upside creates a near term value driver that may not be fully reflected in the share price.
Compared with Bristol Myers Squibb's Sotyktu which is also a TYK2 inhibitor approved in twenty twenty two envudeucitinib appears to have higher efficacy rates in the pivotal trials. Higher efficacy may allow the drug to achieve better formulary placement and preferential reimbursement terms. Safety signals from the trials have been manageable with no major safety concerns reported to date. A favorable safety profile combined with strong efficacy could support a premium price relative to existing options. These competitive advantages could help Alumis gain traction in a crowded biologics market.
The stock price reaction to the trial news saw shares rise more than one hundred fifty% to around twenty one dollars indicating strong investor enthusiasm. However the current market capitalization still leaves room for further appreciation if the drug reaches peak sales estimates. Analysts have noted that the valuation does not yet fully reflect the potential royalty stream from a partnership or the incremental value of lupus data. This gap between current pricing and fundamental upside suggests the market may be underestimating the company’s future cash flows. As a result there is upside potential for investors who believe in the drug’s long term prospects.
The trial results showed that about sixty five% of patients achieved a ninety% or greater improvement in skin symptoms after twenty four weeks of treatment. This level of efficacy exceeds what was seen with many existing therapies and suggests the drug could deliver a best in class profile. More than forty% of patients experienced complete skin clearance which is a meaningful endpoint for regulators and payers. Such high rates of PASI 90 and PASI 100 responses indicate a strong therapeutic signal that may support premium pricing. The data were described as stronger than expected by analysts which implies the market may have underestimated the drug's potential. Overall the efficacy data create a solid foundation for future commercial success.
The addressable market for moderate to severe plaque psoriasis in the United States exceeds eight million patients according to the National Psoriasis Foundation. Globally the number of affected individuals is substantially larger providing a multi billion dollar opportunity. Capturing even a modest share of this patient base could translate into significant annual revenues for the company. The drug’s mechanism targeting TYK2 offers a differentiated approach compared with older cytokine blockers. Expansion into additional immune mediated diseases such as lupus further broadens the potential market. These factors together suggest a long runway for growth beyond the initial psoriasis indication.
Alumis has stated it plans to seek U S regulatory approval for envudeucitinib in the second half of the current year. A successful approval would allow the company to begin commercial sales and generate cash flow sooner than many investors anticipate. Management has also indicated that there should be interest from potential strategic partners for the asset. A partnership or licensing deal could provide upfront payments milestones and royalties reducing the need for dilutive financing. The combination of a near term regulatory catalyst and partnership upside creates a near term value driver that may not be fully reflected in the share price.
Compared with Bristol Myers Squibb's Sotyktu which is also a TYK2 inhibitor approved in twenty twenty two envudeucitinib appears to have higher efficacy rates in the pivotal trials. Higher efficacy may allow the drug to achieve better formulary placement and preferential reimbursement terms. Safety signals from the trials have been manageable with no major safety concerns reported to date. A favorable safety profile combined with strong efficacy could support a premium price relative to existing options. These competitive advantages could help Alumis gain traction in a crowded biologics market.
The stock price reaction to the trial news saw shares rise more than one hundred fifty% to around twenty one dollars indicating strong investor enthusiasm. However the current market capitalization still leaves room for further appreciation if the drug reaches peak sales estimates. Analysts have noted that the valuation does not yet fully reflect the potential royalty stream from a partnership or the incremental value of lupus data. This gap between current pricing and fundamental upside suggests the market may be underestimating the company’s future cash flows. As a result there is upside potential for investors who believe in the drug’s long term prospects.
The psoriasis treatment arena is already crowded with several effective biologics and oral agents that have demonstrated high response rates. Bristol Myers Squibb's Sotyktu which shares the same TYK2 mechanism has already secured approval and begun gaining market share. Differentiating envudeucitinib on efficacy alone may be challenging if safety or convenience factors are not superior. Physicians may be reluctant to switch patients from established therapies without clear added benefit. This competitive intensity could limit the drug’s ability to capture a meaningful share of the eight million U S patient pool.
Regulatory approval is never guaranteed and the FDA may request additional data or a larger safety database before granting marketing authorization. The company plans to file in the second half but any delay would push revenue realization further into the future. A complete response letter would require additional clinical work increasing costs and extending the timeline. Until approval is secured the stock remains exposed to binary event risk. Investors must weigh the probability of approval against the current valuation which already reflects optimistic expectations.
Alumis is a relatively small biotech with limited commercial infrastructure and sales force. Successfully launching a new dermatology product would require building a national sales team or entering into a co promotion agreement. Relying on a partner for commercialization introduces execution risk and may reduce the economic upside for shareholders. If a partnership is not secured on favorable terms the company could face challenges in achieving adequate market penetration. The need for external support adds a layer of uncertainty to the near term financial outlook.
The lupus program is still in a mid stage trial and data are not expected until twenty twenty six. Mid stage studies in autoimmune diseases have a history of failing to replicate early signals. Negative or inconclusive lupus results would not only disappoint investors but could also raise questions about the drug’s broader immune modulation profile. A setback in lupus could also affect partnership discussions as potential collaborators may prefer assets with more advanced data. The reliance on a future readout for pipeline validation creates a significant risk factor.
Funding the ongoing trials and any potential commercial launch will require substantial cash. Alumis may need to tap the equity markets through secondary offerings or convertible debt to finance operations. Such dilutive events could depress the share price and reduce existing shareholders’ ownership stakes. Even if a partnership is secured the upfront cash may not be sufficient to cover all development costs. The company’s cash burn rate combined with uncertain revenue timing creates a financing overhang that could weigh on the stock.
The psoriasis treatment arena is already crowded with several effective biologics and oral agents that have demonstrated high response rates. Bristol Myers Squibb's Sotyktu which shares the same TYK2 mechanism has already secured approval and begun gaining market share. Differentiating envudeucitinib on efficacy alone may be challenging if safety or convenience factors are not superior. Physicians may be reluctant to switch patients from established therapies without clear added benefit. This competitive intensity could limit the drug’s ability to capture a meaningful share of the eight million U S patient pool.
Regulatory approval is never guaranteed and the FDA may request additional data or a larger safety database before granting marketing authorization. The company plans to file in the second half but any delay would push revenue realization further into the future. A complete response letter would require additional clinical work increasing costs and extending the timeline. Until approval is secured the stock remains exposed to binary event risk. Investors must weigh the probability of approval against the current valuation which already reflects optimistic expectations.
Alumis is a relatively small biotech with limited commercial infrastructure and sales force. Successfully launching a new dermatology product would require building a national sales team or entering into a co promotion agreement. Relying on a partner for commercialization introduces execution risk and may reduce the economic upside for shareholders. If a partnership is not secured on favorable terms the company could face challenges in achieving adequate market penetration. The need for external support adds a layer of uncertainty to the near term financial outlook.
The lupus program is still in a mid stage trial and data are not expected until twenty twenty six. Mid stage studies in autoimmune diseases have a history of failing to replicate early signals. Negative or inconclusive lupus results would not only disappoint investors but could also raise questions about the drug’s broader immune modulation profile. A setback in lupus could also affect partnership discussions as potential collaborators may prefer assets with more advanced data. The reliance on a future readout for pipeline validation creates a significant risk factor.
Funding the ongoing trials and any potential commercial launch will require substantial cash. Alumis may need to tap the equity markets through secondary offerings or convertible debt to finance operations. Such dilutive events could depress the share price and reduce existing shareholders’ ownership stakes. Even if a partnership is secured the upfront cash may not be sufficient to cover all development costs. The company’s cash burn rate combined with uncertain revenue timing creates a financing overhang that could weigh on the stock.